Spots Global Cancer Trial Database for t(9;22)
Every month we try and update this database with for t(9;22) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia | NCT03263572 | Accelerated Pha... Acute Lymphobla... BCR-ABL1 Fusion... Blast Phase Chr... Philadelphia Ch... Recurrent Acute... Refractory Acut... t(9;22) | Blinatumomab Cytarabine Methotrexate Ponatinib | 18 Years - | M.D. Anderson Cancer Center | |
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. | NCT00390793 | Acute Lymphobla... BCR-ABL1 Fusion... Blast Phase Chr... Philadelphia Ch... Recurrent Acute... t(9;22) | Cyclophosphamid... Cytarabine Dasatinib Dexamethasone Doxorubicin Methotrexate Prednisone Vincristine | 18 Years - | M.D. Anderson Cancer Center | |
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia | NCT03263572 | Accelerated Pha... Acute Lymphobla... BCR-ABL1 Fusion... Blast Phase Chr... Philadelphia Ch... Recurrent Acute... Refractory Acut... t(9;22) | Blinatumomab Cytarabine Methotrexate Ponatinib | 18 Years - | M.D. Anderson Cancer Center | |
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia | NCT03576547 | Blast Phase Chr... Philadelphia Ch... Recurrent Acute... Recurrent Chron... Refractory Acut... Refractory Chro... t(9;22) | Dexamethasone Ponatinib Hydro... Rituximab Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia | NCT03576547 | Blast Phase Chr... Philadelphia Ch... Recurrent Acute... Recurrent Chron... Refractory Acut... Refractory Chro... t(9;22) | Dexamethasone Ponatinib Hydro... Rituximab Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. | NCT00390793 | Acute Lymphobla... BCR-ABL1 Fusion... Blast Phase Chr... Philadelphia Ch... Recurrent Acute... t(9;22) | Cyclophosphamid... Cytarabine Dasatinib Dexamethasone Doxorubicin Methotrexate Prednisone Vincristine | 18 Years - | M.D. Anderson Cancer Center |